CRISPR Therapeutics (NASDAQ:CRSP) Stock Price Down 3.9% - Here's Why

CRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report)'s share price fell 3.9% during mid-day trading on Tuesday . The stock traded as low as $40.82 and last traded at $41.63. 586,834 shares changed hands during mid-day trading, a decline of 74% from the average session volume of 2,241,707 shares. The stock had previously closed at $43.34.

Analysts Set New Price Targets

Several research firms recently weighed in on CRSP. Chardan Capital reduced their target price on shares of CRISPR Therapeutics from $94.00 to $84.00 and set a "buy" rating on the stock in a report on Thursday, February 13th. Morgan Stanley increased their target price on CRISPR Therapeutics from $30.00 to $32.00 and gave the company an "underweight" rating in a research note on Friday, February 14th. The Goldman Sachs Group reduced their price target on CRISPR Therapeutics from $66.00 to $57.00 and set a "neutral" rating on the stock in a research report on Thursday, February 13th. Citigroup dropped their price objective on shares of CRISPR Therapeutics from $89.00 to $82.00 and set a "buy" rating on the stock in a research note on Tuesday, February 18th. Finally, JMP Securities restated a "market outperform" rating and issued a $86.00 target price on shares of CRISPR Therapeutics in a research note on Thursday, February 13th. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have assigned a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $73.11.

Remove Ads

CRISPR Therapeutics Stock Up 0.7 %

The firm's 50 day simple moving average is $43.03 and its two-hundred day simple moving average is $45.63. The stock has a market cap of $3.63 billion, a P/E ratio of -9.70 and a beta of 1.77.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last released its quarterly earnings data on Tuesday, February 11th. The company reported ($0.44) earnings per share for the quarter, topping the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. As a group, equities analysts predict that CRISPR Therapeutics AG will post -5.16 EPS for the current year.

Insider Buying and Selling

In other CRISPR Therapeutics news, Director John Greene acquired 7,000 shares of the firm's stock in a transaction that occurred on Wednesday, February 26th. The stock was acquired at an average cost of $44.85 per share, with a total value of $313,950.00. Following the acquisition, the director now directly owns 7,000 shares of the company's stock, valued at $313,950. This represents a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Samarth Kulkarni sold 18,360 shares of CRISPR Therapeutics stock in a transaction on Wednesday, February 19th. The shares were sold at an average price of $55.20, for a total value of $1,013,472.00. Following the sale, the chief executive officer now directly owns 171,613 shares in the company, valued at $9,473,037.60. The trade was a 9.66 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 32,381 shares of company stock worth $1,608,243 in the last three months. 4.10% of the stock is owned by insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. ARK Investment Management LLC grew its position in CRISPR Therapeutics by 19.7% in the 4th quarter. ARK Investment Management LLC now owns 8,973,064 shares of the company's stock valued at $353,180,000 after buying an additional 1,474,439 shares in the last quarter. T. Rowe Price Investment Management Inc. boosted its holdings in shares of CRISPR Therapeutics by 39.2% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,811,708 shares of the company's stock valued at $150,029,000 after acquiring an additional 1,074,238 shares in the last quarter. Capital International Investors increased its stake in shares of CRISPR Therapeutics by 10.3% during the fourth quarter. Capital International Investors now owns 8,743,523 shares of the company's stock valued at $344,145,000 after acquiring an additional 816,789 shares during the period. Baker BROS. Advisors LP raised its holdings in CRISPR Therapeutics by 743.1% during the third quarter. Baker BROS. Advisors LP now owns 843,075 shares of the company's stock worth $39,608,000 after purchasing an additional 743,075 shares in the last quarter. Finally, State Street Corp lifted its position in CRISPR Therapeutics by 25.0% in the third quarter. State Street Corp now owns 2,992,988 shares of the company's stock worth $140,611,000 after purchasing an additional 599,304 shares during the period. 69.20% of the stock is owned by institutional investors and hedge funds.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.